Gene therapy for rare retinal disorder to cost $425,000 per eye

A one-time treatment with Luxturna, the first US Food and Drug Administration-approved gene therapy for an inherited ...

Posted: Jan 4, 2018 9:16 AM
Updated: Jan 4, 2018 9:16 AM

A one-time treatment with Luxturna, the first US Food and Drug Administration-approved gene therapy for an inherited disorder, will cost $425,000 per eye.

Spark Therapeutics Inc., the Philadelphia-based maker of voretigene neparvovec, announced Wednesday in a statement that it reached an agreement in principle with Harvard Pilgrim and affiliates of-Express Scripts to make the one-time treatment available to patients with a rare genetic defect that often leads to blindness.

Luxturna, a one-time treatment, corrects a genetic mutation that can lead to blindness

Spark Therapeutics set the price for the gene therapy at $425,000 per eye

The mutation affects both eyes, usually at the same pace, so most patients would need treatment for both eyes, a Spark Therapeutics spokeswoman said.

In some cases, the gene therapy will be available under an "outcomes-based rebate arrangement." The company also stated that its proposal to the Centers for Medicare and Medicaid Services, the government program that covers about 100 million Americans, would allow installment payments for the drug.

"For a one-time therapy, like Luxturna, a non-traditional payment and distribution model is necessary to ensure needs of all parties -- patients, payers and providers -- are addressed," said Jennifer Luddy, a spokeswoman for Express Scripts.

At least one patient advocate disagrees.

"The new payment models announced today are merely a way to disguise a price that is simply too high," David Mitchell, president and founder of Patients For Affordable Drugs, said in a statement. "Spark Therapeutics is charging as much for Luxturna as they think they can get away with."

Spark Therapeutics CEO Jeff Marrazzo co-authored a recent blog post in the journal Health Affairs that said "the current payment system -- accustomed to ongoing treatment of chronic diseases -- creates significant challenges" for gene therapies and other treatments.

One-time-only treatments for rare genetic disorders are still unique, he noted.

The drug is intended for patients with retinal dystrophy due to a mutation of the RPE65 gene. This rare genetic defect causes severe visual impairment beginning in infancy and can eventually lead to blindness. The company believes the total "population in the US, Europe and select additional markets in the Americas and Asia/Pacific is up to approximately 6,000 individuals" who have the mutation targeted by Luxturna, explained Monique da Silva, a spokeswoman for Spark Therapeutics.

The drug will be available in the United States in early spring, with an estimated 1,000 to 2,000 people in the US standing to benefit from this treatment, according to Spark.

Luxturna is only the third gene therapy approved for use in the United States; two others were also approved in 2017. This is the first to correct an inherited genetic mutation.

Luxturna-is a liquid that is injected directly into the eye with a microscopic needle during a surgical procedure. The drug supplies a third gene -- a normal RPE65 gene -- to cells in the retina, a layer of tissue lining the back of the eye.-This third version of the gene does not remove or replace the two mutated genes causing the disease, which remain inside the cells. However, the normal gene delivered by the treatment is able to function within the retinal cells and correct vision problems.

In the phase 3 clinical trial, 27 out of 29 participants -- 93% -- who received the gene therapy demonstrated a gain in functional vision as assessed by a mobility test performed in a maze, according to the company. Risks of the treatment include cataracts, elevated eye pressure, retinal tears and holes and inflammation.

The company's offer of unusual payer models, including rebates and installment payments, will "help ensure patients' individual financial situation does not hinder access to treatment," da Silva said.

"New technologies such as gene and cell therapies hold out the potential to transform medicine," FDA Commissioner Dr. Scott Gottlieb-said in a statement announcing the August approval of Kymriah, considered to be the first gene therapy to be approved for the US market.

Kymriah is a leukemia treatment made by pharmaceutical giant Novartis. Similar to Luxturna, Kymriah is a one-time treatment, and its price tag is $475,000. However, Novartis said this price will not be charged to patients who do not respond within a month of treatment.

West Lafayette
Broken Clouds
40° wxIcon
Hi: 46° Lo: 29°
Feels Like: 33°
Kokomo
Clear
38° wxIcon
Hi: 43° Lo: 29°
Feels Like: 31°
Rensselaer
Overcast
37° wxIcon
Hi: 44° Lo: 28°
Feels Like: 30°
Fowler
Overcast
37° wxIcon
Hi: 45° Lo: 28°
Feels Like: 30°
Williamsport
Broken Clouds
40° wxIcon
Hi: 46° Lo: 28°
Feels Like: 33°
Crawfordsville
Overcast
42° wxIcon
Hi: 46° Lo: 28°
Feels Like: 36°
Frankfort
Overcast
40° wxIcon
Hi: 45° Lo: 29°
Feels Like: 33°
Delphi
Overcast
40° wxIcon
Hi: 45° Lo: 28°
Feels Like: 32°
Monticello
Overcast
40° wxIcon
Hi: 45° Lo: 28°
Feels Like: 32°
Logansport
Clear
37° wxIcon
Hi: 42° Lo: 27°
Feels Like: 37°
Fair Weather Continues
WLFI Radar
WLFI Temps
WLFI Planner

Indiana Coronavirus Cases

Data is updated nightly.

Cases: 350970

Reported Deaths: 5973
CountyCasesDeaths
Marion47763893
Lake30007480
Allen20256333
Elkhart18510245
St. Joseph18319243
Hamilton14971181
Vanderburgh10862134
Tippecanoe991133
Porter915392
Johnson7484177
Hendricks7143163
Vigo6580105
Monroe591453
Madison5732125
Clark564884
Delaware5434108
LaPorte5171104
Kosciusko501846
Howard400578
Bartholomew367565
Warrick360574
Wayne355192
Floyd348878
Marshall333949
Cass319132
Grant315652
Hancock307762
Noble284750
Boone274656
Henry272141
Dubois262934
Jackson255237
Morgan251845
Dearborn249733
Gibson217033
Shelby212861
Knox207722
DeKalb204438
Clinton202224
Lawrence200549
Wabash190623
Miami188118
Adams187424
Daviess174246
Montgomery167029
Jasper165015
Ripley164521
Fayette163837
Steuben163016
Harrison162024
LaGrange156533
Whitley156516
Huntington147211
White147024
Putnam142530
Wells142533
Decatur141846
Randolph139524
Clay138026
Jefferson137618
Posey133620
Scott124024
Greene117954
Jay113315
Sullivan109018
Jennings102415
Starke100828
Spencer9578
Fulton94219
Fountain9228
Perry88021
Washington8789
Franklin79528
Carroll79313
Orange74428
Vermillion72810
Owen71410
Parke6796
Tipton66527
Blackford62715
Rush6278
Newton62113
Pike57421
Pulaski48020
Benton4423
Brown3995
Martin3896
Crawford3421
Union2972
Switzerland2765
Warren2763
Ohio2477
Unassigned0285

COVID-19 Important links and resources

As the spread of COVID-19, or as it's more commonly known as the coronavirus continues, this page will serve as your one-stop for the resources you need to stay informed and to keep you and your family safe. CLICK HERE

Closings related to the prevention of the COVID-19 can be found on our Closings page.

Community Events